9 Meters Biopharma, Inc. announced plans to conduct a Phase 3 trial with vurolenatide in patients with short bowel syndrome (SBS). However, following further consideration of feedback received previously from the U.S. Food and Drug Administration (FDA) and input from thought leaders and investors, the Company now believes an additional Phase 2 trial may maximize the potential for vurolenatide. In addition, as the Company continues to assess various strategic alternatives, if and when funding is available, the Company will update on the initiation of the timing of this Phase 2 trial.